Avanos Medical, Inc.

Avanos Medical, Inc.

AVNS
Avanos Medical, Inc.US flagNew York Stock Exchange
24.96
USD
-0.02
- -
1.17BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
36.06
35.93
10.93
12.15
13.07
13.82
14.66
14.95
12.2
14.59
14.45
14.95
15.14
15.43
Basic EPS, GAAP
3.32
0.58
-9.15
0.85
1.69
1.22
-0.96
-0.57
0.13
1.08
-1.33
-8.52
-1.57
-1.6
Free Cash Flow per Basic Share
4.81
3.18
2.1
4.05
3.08
-3.08
-1.57
-0.05
1.81
1.94
0.7
2.19
1.61
0.79
Dividend per Share
- -
14.61
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
0.17
-8.98
-8.13
-6.4
-5.12
-6.05
-6.59
-6.3
-5.39
-6.75
-15.36
-16.83
-16.7
Tangible Book Value per Share
10.92
-0.93
0.59
3.69
6.45
7.32
5.88
6.2
6.81
6.33
4.31
5.67
5.73
5.89
Basic Weighted Avg Shares
47
47
47
47
47
47
48
48
48
47
47
46
46
46
Sales/Revenue/Turnover
1,678
1,672
509
566
612
652
698
715
587
684
673
688
701
716
Operating Margin (%)
13.43
5.64
-26.66
-18.92
-7.05
0.08
-7.98
-6.45
-6.64
5.19
0.62
5.89
2.2
1.96
Depreciation Expense
69
85
65
65
60
34
37
43
38
48
46
46
39
40
Net Income, GAAP
155
27
-426
40
79
58
-46
-27
6
50
-62
-392
-73
-74
Effective Tax Rate (%)
32.13
70.29
- -
- -
- -
- -
- -
- -
- -
19.48
- -
- -
- -
241.23
Profit Margin (%)
9.22
1.62
-83.75
7.03
12.97
8.81
-6.58
-3.81
1.07
7.38
-9.18
-57.01
-10.4
-10.39
Working Capital
275
328
361
269
771
449
326
301
288
433
252
228
190
194
LT Debt
- -
623
578
579
541
248
311
233
173
259
188
150
111
117
Total Equity
2,079
1,491
1,055
1,102
1,215
1,297
1,265
1,256
1,271
1,291
1,236
828
778
782
Return on Invested Capital (%)
7.19
1.32
- -
- -
- -
- -
- -
- -
- -
1.88
- -
- -
- -
- -
Return on Capital (%)
352.32
8.94
- -
- -
- -
- -
- -
- -
- -
-128.4
- -
- -
- -
1.53
Return on Common Equity (%)
- -
694.87
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
19
18
21
LT Borrowings
93
90
87
LT Finance Leases
21
20
30
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
46
46
47
Market Capitalization
534
520
650

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
351
355
325
Cash, Cash Equivalents & STI
70
90
66
Accounts Receivable, Net
111
104
103
Inventories
151
148
141
Total Current Liabilities
148
165
131
Payables & Accruals
129
147
110
ST Debt
19
18
21
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-2.23%
-8.11%
-6.07%
Free Cash Flow
-374.39%
-693.45%
-25.82%
Net Income, GAAP
55.1%
161.82%
-81.41%
Sales/Revenue/Turnover
3.65%
0.24%
1.95%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
166
172
170
180
688
2025
168
175
178
181
701
2026
182
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
0.04
0.09
-8.64
-8.52
2025
0.14
-1.66
-0.03
-0.03
-1.57
2026
0.11
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

MCPAPIChat
CEO
David C. Pacitti
Full Time Employees
2,227
Sector
Healthcare
Industry
Medical - Devices
Address
5405 Windward Parkway Alpharetta GA United States of America 30004
IPO Date
Oct 21, 2014
Website
avanos.com
Business
Avanos Medical, Inc. Avanos Medical, Inc. (AVNS) develops, manufactures and markets medical devices focused on pain management and recovery and specialty nutrition systems including enteral feeding. The company offers a broad portfolio of products such as the COOLIEF cooled radiofrequency ablation system and TRIDENT hybrid cannula for chronic pain treatment via radiofrequency nerve ablation; ON-Q elastomeric and ambIT electronic ambulatory pain pumps for post-surgical pain control; GAME READY cryocompression therapy systems for injury and surgical recovery; TriVisc and GenVisc850 hyaluronic acid injections for osteoarthritis knee pain; MIC-KEY low-profile and MIC PEG feeding tubes, CORTRAK2 enteral access system, CORFLO nasogastric/nasointestinal tubes, NEOMED neonatal feeding solutions, FARRELL valve system for gastric decompression and CORGRIP tube retention devices for digestive health and enteral nutrition across neonates, pediatrics and adults. Avanos Medical serves hospitals, ambulatory surgery centers, pain clinics, critical care units, neonatologists and healthcare providers worldwide in over 90 countries through direct sales and distributors. Headquartered in Alpharetta, Georgia and founded in 2014 as a spin-off from Kimberly-Clark Corporation, the company rebranded from Halyard Health in 2018 and operates two primary segments of pain management and chronic care. In September 2025, Avanos Medical acquired Nexus Medical, LLC, integrating its TKO anti-reflux needleless connector technology to enhance nutrition and medication delivery in critical care, neonatal and pediatric intensive care units, bolstering the specialty nutrition systems division with immediate revenue and earnings accretion. The company reported double-digit growth in its specialty nutrition systems segment during third quarter 2025, driven by strong product demand and the Nexus integration.

Company News

MCPAPIChat
  • Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders?

  • The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—TMHC, CZR, XOMA, and AVNS

  • Avanos Medical (AVNS) Up 1.1% Since Last Earnings Report: Can It Continue?

  • Are CZR, AVNS, GBTG Obtaining Fair Deals for their Shareholders?

  • $HAREHOLDER ALERT: The M&A Class Action Launches Legal Inquiry for the Merger--AFBI, QXO, BLD, and AVNS

  • New Strong Sell Stocks for May 15th

  • Deciphering Avanos Medical (AVNS) International Revenue Trends

  • AVNS Gains After Posting Q1 Earnings Miss & Revenue Beat, Margins Down

  • BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Helix Energy Solutions Group, Inc. (NYSE – HLX), TopBuild Corp. (NYSE – BLD), Avanos Medical, Inc. (NYSE – AVNS), Affinity Bancshares (Nasdaq – AFBI)

  • Avanos Medical (AVNS) Lags Q1 Earnings Estimates

  • Avanos Medical, Inc. Announces First Quarter 2026 Results

  • Shareholder Alert: Ademi LLP investigates whether Avanos Medical Inc. is obtaining a Fair Price for Public Shareholders

  • Avanos Medical Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avanos Medical, Inc. - AVNS

  • Avanos Stock Surged on $1.27 Billion AIP Buyout Deal at 72% Premium

  • Avanos Medical Inc (AVNS) Stock Up 69.5% but GF Value Says Overvalued -- GF Score: 73/100

  • This Healthcare Stock Is Rising 69%. It's Getting Bought Out for a Big Premium.

  • $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avanos Medical, Inc. (NYSE: AVNS)

  • Shareholder Alert: Ademi LLP investigates whether Avanos Medical Inc. is obtaining a Fair Price for Public Shareholders

  • AVNS Stock Alert: Halper Sadeh LLC is Investigating Whether Avanos Medical, Inc. is Obtaining a Fair Price for its Shareholders

  • AIP to take Avanos Medical private in a deal valued at about $1.27 billion